During 2013 to 2016, more than two million people in the United States had current hepatitis C virus infection.
Hepatitis E infection identified in 56-year-old man who had received a liver transplant in May 2017.
The list price for the generics is $24,000 for the most common course of therapy.
The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC.
Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.
The FDA has approved Mulpleta for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Hepatitis B core Antibody (anti-HB c+) organs may be a safe and ethical transplant option in an era where increased medical knowledge has enabled greater treatment for hepatitis.
Meeting World Health Organization targets for chronic hepatitis B by 2030 will be cost-effective.
A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.
The Canadian Medical Association provided an updated evidence-based recommendations for the treatment of patients with chronic hepatitis C virus.
The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.
Alcohol use disorder in patients with HCV infection is associated with increased symptoms of depression and anxiety compared with patients with HCV and no history of alcohol abuse.
Universal screening is the most effective strategy for hepatitis C virus in France.
The sBLA is based on results from the Phase 2 KEYNOTE-224 trial, which enrolled 104 individuals with advanced hepatocellular carcinoma previously treated with sorafenib who were either intolerant to or showed progression of disease after treatment.
For patients with HCV infection with end-stage renal disease, transplant of an HCV-infected kidney followed by treatment is more cost-effective than transplant of an HCV-uninfected kidney.
Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.
Vemlidy, a nucleoside analogue (reverse transcriptase inhibitor), is currently approved to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
From 2007 to 2015, the majority of initial hepatitis A, B, and A/B vaccinations were administered by primary care providers.
For the analysis, study authors looked at data specifically for patients with type 2 diabetes aged 60 to 70 years.
For older patients with hepatitis C virus, direct-acting antiviral therapy is effective.
Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.
Real-world data have demonstrated no rise in the development of incident liver cirrhosis among patients with psoriasis and either CHB or CHC who have received long-term MTX therapy.
Post-transplant hepatitis C treatment increases access to transplant and reduces waitlist time among hepatitis C-positive patients awaiting kidney transplantation.
Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
The discontinuation is voluntary and is not related to product quality, safety or efficacy.
Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Homeopathy No Better Than Placebo for Respiratory Infections in Children
- CDC Director Says Congo Ebola Outbreak May Be Uncontainable
- 10th Child Dies in Adenovirus Outbreak at NJ Facility
- Depression and Alcohol Misuse Lower Odds of Achieving Viral Suppression in HIV
- Antibiotics and Failure Rates During 2-Stage Exchange Arthroplasty
- Oral Urinary Tract Infection Treatments
- Treating Pseudomonas aeruginosa Infections: Highlights From IDWeek 2018
- Local Gentamicin Application Ineffective in Treatment of Periprosthetic Joint Infection
- High-Dose Influenza Vaccination May Benefit Transplant Recipients
- Social Medicine: The Effect of Social Media on the Anti-Vaccine Movement
- GERD Diagnosis and Management Guidelines
- Improved Care Needed for People With HIV in Prison and After Release
- Novel Point of Care Respiratory Viral Testing Service Shows Potential
- A New Nucleotide Analog Is Well Tolerated, Efficacious Against HCV Genotype 1-4
- Many Linens Delivered To US Hospitals Contaminated With Mucorales Mold